Ann Oncol

1. CANTORE T, Hoang DT, Pal LR, Stemmer A, et al
   Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.
   Ann Oncol. 2026 May 26:S0923-7534(26)00884-7. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   
2. PAGANI O, Niman SM, Ruggeri M, Peccatori FA, et al
   Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.
   Ann Oncol. 2026 May 28:S0923-7534(26)00883-5. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. VERTIDO A, McKenzie T, Othieno A, Quirarte A, et al
   Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
   Ann Surg Oncol. 2025;32:8710-8719.
   

   >> Share

   
   
4. DE CARDOSO DIAS I, Mora HF, Peleteiro B, Fougo JL, et al
   Breast-Conserving Oncoplastic Surgery Stratification: Morbidity Retrospective Analysis and its Association with Procedure Complexity Level.
   Ann Surg Oncol. 2025;32:8769-8779.
   

   >> Share

   
   
5. BRABENDER D, Siegel E, Culver JO, Comeaux JG, et al
   Identification of Patients at Elevated Cancer Risk through a Community-Based Genetic Testing Program.
   Ann Surg Oncol. 2025;32:9041-9049.
   

   >> Share

   
   
6. WANIS KN, Krasniqi R, Sun SX, Resetkova E, et al
   ASO Visual Abstract: Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis After Neoadjuvant Therapy for Patients with Clinically Node-Negative Hormone Receptor-Positive, HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2026 May 26. doi: 10.1245/s10434-026-19872.
   

   >> Share

   
   
7. STANCZYK M, Cheung TC, Lang JE
   The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer.
   Ann Surg Oncol. 2026 May 29. doi: 10.1245/s10434-026-19672.
   

   >> Share

   
   

   
   Anticancer Res

8. RADES D, Streubel MK, Staackmann C, Doehring L, et al
   Standard Clinical Characteristics Fail to Predict Mild Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients.
   Anticancer Res. 2026;46:3425-3430.
   

   >> Share

   
   

   
   BMC Cancer

9. CELIK O, Ozgul H, Kulaksizoglu S, Oner OZ, et al
   New biomarker in the early diagnosis of breast cancer: adiponectin, asprosin, adropin, and resistin.
   BMC Cancer. 2026 May 22. doi: 10.1186/s12885-026-16183.
   

   >> Share

   
   
10. OZTURK C, Cubukcu SS, Sen B, Ozturk AE, et al
    High TROP-2 expression as a predictor of poor neoadjuvant chemotherapy response in luminal B breast cancer: a retrospective clinicopathological study.
    BMC Cancer. 2026 May 23. doi: 10.1186/s12885-026-16227.
    

    >> Share

    
    
11. ALLFELT A, Bendahl PO, Dihge L, Ohlsson M, et al
    Human factors validation study of an artificial neural network?based preoperative decision?support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN99301435).
    BMC Cancer. 2026 May 28. doi: 10.1186/s12885-026-16161.
    

    >> Share

    
    
12. WIGUNA IGWW, Sadeva IGKA, Mamangdean CT, Mahayana NPK, et al
    Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16207.
    

    >> Share

    
    
13. SHEERVALILOU M, Sargazi S, Shahraki S, Sheervalilou R, et al
    Integrated in vitro and bioinformatic analysis of autophagy?related gene expression modulated by Fe(2)O(3)/Au core-shell nanoparticles in breast cancer cells.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16068.
    

    >> Share

    
    

    
    Breast Cancer

14. TANAKA K, Shimomura A, Ishitobi M, Yamanaka T, et al
    Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.
    Breast Cancer. 2026 May 29. doi: 10.1007/s12282-026-01874.
    

    >> Share

    
    
15. NAJARI NABI M, Asgari Oskoei O, Mohammad Bagheri Parvin D, Taghizadeh-Teymorloei M, et al
    Evaluation of serum microRNA-9-5p expression and its predicted target genes as potential biomarkers for breast cancer.
    Breast Cancer. 2026 May 29. doi: 10.1007/s12282-026-01866.
    

    >> Share

    
    
16. MURATA T, Yoshida M, Watase C, Maeda H, et al
    Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1-3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis.
    Breast Cancer. 2026 May 23. doi: 10.1007/s12282-026-01871.
    

    >> Share

    
    
17. TAJI T, Uemura Y, Kimura Y, Maeda N, et al
    Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness).
    Breast Cancer. 2026 May 23. doi: 10.1007/s12282-026-01867.
    

    >> Share

    
    

    
    Breast Cancer (Auckl)

18. ESSILFIE NK, Abakah A, Etsey M, Ofori-Amanfo D, et al
    Impact of Distinct Molecular and Immunological Features of Breast Cancer on the Effectiveness of Therapies in Ghana.
    Breast Cancer (Auckl). 2026;20:11782234261451687.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

19. CAI M, Lu T, Lv S, Zheng Z, et al
    Hsa_circ_0000520 Promotes Invasion and Metastasis of Breast Cancer Cells by Targeting HSP90AA1.
    Breast Cancer (Dove Med Press). 2026;18:600770.
    

    >> Share

    
    
20. ZHANG Z, Liu Z, Li C, Wang F, et al
    The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:592003.
    

    >> Share

    
    
21. LIU J, Peng X, Yang Y, Huang X, et al
    A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection.
    Breast Cancer (Dove Med Press). 2026;18:600575.
    

    >> Share

    
    

    
    Breast Cancer Res

22. WOO H, Han S, Heo J, Cho J, et al
    Germline APOE epsilon2 homozygosity and reduced risk of breast cancer: a population-based cohort study.
    Breast Cancer Res. 2026 May 22. doi: 10.1186/s13058-026-02308.
    

    >> Share

    
    
23. ISHIKAWA T, Uemura Y, Seki H, Kitada M, et al
    Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.
    Breast Cancer Res. 2026 May 29. doi: 10.1186/s13058-026-02313.
    

    >> Share

    
    
24. BUYUKKUSCU A, Isleyen ZS, Ekinci OB, Atasever T, et al
    Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study.
    Breast Cancer Res. 2026 May 28. doi: 10.1186/s13058-026-02312.
    

    >> Share

    
    
25. ALI FAIRBAIRN S, Kim K, Cowan RW, Lessey LR, et al
    Kaiso modulates androgen receptor expression in triple-negative breast cancer.
    Breast Cancer Res. 2026 May 28. doi: 10.1186/s13058-026-02299.
    

    >> Share

    
    
26. VETA DARKOVSKI J, Michelon I, Gazzoni G, Mamede I, et al
    CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data.
    Breast Cancer Res. 2026;28:100.
    

    >> Share

    
    
27. SERVITJA S, Carrasco E, Andres R, Rodriguez-Lescure A, et al
    Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.
    Breast Cancer Res. 2026 May 25. doi: 10.1186/s13058-026-02300.
    

    >> Share

    
    
28. LIU Q, Fan J, Peng W, Deng S, et al
    ZNF831 suppresses triple-negative breast cancer progression through NLRP3-associated pyroptotic signaling and M1-like macrophage phenotypic remodeling.
    Breast Cancer Res. 2026 May 23. doi: 10.1186/s13058-026-02307.
    

    >> Share

    
    
29. OSHI M, Sugimori M, Kawashima K, Gandhi S, et al
    TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.
    Breast Cancer Res. 2026 May 22. doi: 10.1186/s13058-026-02305.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

30. LEVEE A, Santos B, Wong M, Ruel N, et al
    Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.
    Breast Cancer Res Treat. 2026;217:38.
    

    >> Share

    
    

    
    Breast J

31. ZHANG L, Wang J, Tan B, Wang X, et al
    Development and Validation of a Cuproptosis-Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis.
    Breast J. 2026;2026:e6097777.
    

    >> Share

    
    
32. CHAUDHARY U, A S A, A M
    Akkermansia muciniphila-Driven ceRNA Networks Regulate Immune Modulation and Breast Cancer Progression.
    Breast J. 2026;2026:e1416629.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

33. WOO JMP, Chen D, Yarosh R, O'Brien KM, et al
    Thyroid disease and breast cancer risk in the Sister Study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    
34. WANG N, Suo C, Wu Y, Zheng J, et al
    Copper promotes breast cancer through immunometabolic reprogramming: a multi-omics mediation analysis.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Lett

35. LI Z, Sun X, Zheng J, Sun X, et al
    Stress-inducible circSCLT1 scaffolds HNRNPA1/CSDE1 to amplify IL1B/NF-kappaB signaling in TNBC via mRNA stabilization, suppressor degradation, and stress granule shielding.
    Cancer Lett. 2026;652:218561.
    

    >> Share

    
    

    
    Clin Breast Cancer

36. KATO M, Masuda H, Nakayama S, Ohara J, et al
    Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.
    Clin Breast Cancer. 2026 Apr 16:S1526-8209(26)00060.
    

    >> Share

    
    
37. O'SHAUGHNESSY J, Jahan N, Barry AL, Watters RJ, et al
    Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review.
    Clin Breast Cancer. 2026 Apr 15:S1526-8209(26)00062.
    

    >> Share

    
    
38. BERNER AM, Pasin C
    Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care.
    Clin Breast Cancer. 2026 May 10:S1526-8209(26)00076.
    

    >> Share

    
    

    
    Clin Cancer Res

39. SCHMID P, Ma CX, Park YH, Lord S, et al
    Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
    Clin Cancer Res. 2026 May 26. doi: 10.1158/1078-0432.CCR-25-4417.
    

    >> Share

    
    
40. MARTIN M, Rodriguez-Lescure A, Reboredo C, Chen E, et al
    Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.
    Clin Cancer Res. 2026 May 26. doi: 10.1158/1078-0432.CCR-26-0177.
    

    >> Share

    
    

    
    Curr Treat Options Oncol

41. WEINER-GORZEL K, McSorley L, Walshe JM
    Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.
    Curr Treat Options Oncol. 2026;27:30.
    

    >> Share

    
    

    
    Eur J Cancer

42. GUERRERO-ZOTANO A, Gil-Gil M, Williams A, Ruiz-Borrego M, et al
    Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+?/HER2?- metastatic breast cancer: A translational analysis of the GEICAM/2013-02 P
    Eur J Cancer. 2026;242:116817.
    

    >> Share

    
    
43. DI GRAZIA G, Di Lauro V, Morchon-Araujo D, Nucera S, et al
    Association between chemotherapy use and prognosis in young patients with stage I-II ER+?/HER2-negative breast cancer according to Prosigna(R): An international real-world analysis with propensity-score matching.
    Eur J Cancer. 2026;242:116818.
    

    >> Share

    
    

    
    Eur J Surg Oncol

44. BANYS-PALUCHOWSKI M, Solbach C, Kuhn T, Muller V, et al
    AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
    Eur J Surg Oncol. 2026;52:111867.
    

    >> Share

    
    
45. LEE SM, Nam SJ, Kim SW, Lee JE, et al
    Prognostic factors and the role of GnRHa in premenopausal HR+/HER2+ breast cancer achieving pathologic complete response after neoadjuvant chemotherapy.
    Eur J Surg Oncol. 2026;52:111880.
    

    >> Share

    
    

    
    Eur Radiol

46. LEE SE, Lee HS, Park VY, Kim MJ, et al
    AI-CAD for diagnostic mammography: comparison to radiologists according to different indications.
    Eur Radiol. 2026;36:4390-4399.
    

    >> Share

    
    
47. HOVDA T, Holen AS, Hofvind S
    How much radiologist time can be saved by implementing AI in screen-reading mammograms?
    Eur Radiol. 2026;36:4414-4421.
    

    >> Share

    
    
48. DAMIAO SQ, de Melo LB, Carneiro MW, Felipe VC, et al
    Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy.
    Eur Radiol. 2026;36:4403-4413.
    

    >> Share

    
    
49. LARSEN M, Lee CI, Bergan MB, Holen AS, et al
    Performance across different versions of an artificial intelligence model for screen-reading of mammograms.
    Eur Radiol. 2026;36:4422-4433.
    

    >> Share

    
    
50. VATTERONI G, Pirringer-Potsch N, Clauser P, Baltzer PAT, et al
    Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis.
    Eur Radiol. 2026;36:4434-4444.
    

    >> Share

    
    
51. SHARMA N, Theis S, Vogelmann T, Pijnappel R, et al
    Vacuum-assisted breast biopsy vs core needle biopsy: a systematic review and meta-analysis.
    Eur Radiol. 2026;36:4449-4466.
    

    >> Share

    
    
52. SINGH S, Crean R, O'Driscoll J, Cahir C, et al
    Patient perceptions and attitudes towards the use of artificial intelligence in the symptomatic breast unit.
    Eur Radiol. 2026;36:4467-4477.
    

    >> Share

    
    

    
    Int J Oncol

53. TOPHKHANE C, Yang S, Zhao ZJ, Yang X, et al
    [Corrigendum] Cell density?dependent regulation of p73 in breast cancer cells.
    Int J Oncol. 2026;69:85.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

54. WANG J, Ning J, Shaitelman SF, Lin HY, et al
    Radiotherapy de-escalation in breast cancer patients with pathologic complete response: An integrated analysis using real-world and simulated data.
    Int J Radiat Oncol Biol Phys. 2026 May 21:S0360-3016(26)00733.
    

    >> Share

    
    

    
    J Biol Chem

55. LI X, Liu L, Luo L, Deng M, et al
    Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR- high triple-negative breast cancer.
    J Biol Chem. 2026 May 25:113185. doi: 10.1016/j.jbc.2026.113185.
    

    >> Share

    
    
56. SUZUKI Y, Kitayama N, Kudo R, Silwal K, et al
    The cellular stress sensor HSPB1 regulates the membrane localization of amino acid transporter SLC7A5 in breast cancer.
    J Biol Chem. 2026 May 27:113197. doi: 10.1016/j.jbc.2026.113197.
    

    >> Share

    
    

    
    J Natl Cancer Inst

57. RUSSO RG, Hernan MA, Dahabreh IJ, Rimm EB, et al
    Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors.
    J Natl Cancer Inst. 2026 May 29:djag158. doi: 10.1093.
    

    >> Share

    
    

    
    J Pathol

58. VETHENCOURT A, Salgado R, Gonzalez-Suarez E
    Lymph node stromal topology as a hidden regulator of breast cancer outcome: commentary on reticular network analysis(dagger).
    J Pathol. 2026 May 27. doi: 10.1002/path.70085.
    

    >> Share

    
    

    
    J Surg Oncol

59. HENDIZADEH AN, Wen A, Guidi R, Ritz E, et al
    The Impact of Breast Reconstruction on Smoking Cessation Among Patients With Breast Cancer.
    J Surg Oncol. 2026 May 24. doi: 10.1002/jso.70284.
    

    >> Share

    
    

    
    Lancet Oncol

60. DAS M
    Spain expands breast cancer screening programme.
    Lancet Oncol. 2026 May 29:S1470-2045(26)00276.
    

    >> Share

    
    

    
    Nature

61. KLEEMAN SO, Michalski K, Zhao X, Steigerwald R, et al
    Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity.
    Nature. 2026;653:1216-1228.
    

    >> Share

    
    

    
    NPJ Breast Cancer

62. KIM A, Gopalakrishnan P, Suarez-Pizarro M, Chen CC, et al
    USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 May 23. doi: 10.1038/s41523-026-00974.
    

    >> Share

    
    
63. FISCALINI A, Blum K, Fergus K, Hiatt RA, et al
    WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.
    NPJ Breast Cancer. 2026 May 24. doi: 10.1038/s41523-026-00952.
    

    >> Share

    
    
64. PARK P, Kim K, Choi DW, Chae H, et al
    Risk factors for second primary cancer in patients who survive breast cancer.
    NPJ Breast Cancer. 2026 May 27. doi: 10.1038/s41523-026-00975.
    

    >> Share

    
    
65. DOAN TB, Wouters MA, Hu J, Koh JMS, et al
    Potential treatment targets in the whole-tissue proteome of triple negative breast cancer.
    NPJ Breast Cancer. 2026 May 28. doi: 10.1038/s41523-026-00976.
    

    >> Share

    
    
66. BELLET M, Ferrero-Cafiero JM, Bergamino Sirven M, Falato C, et al
    Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.
    NPJ Breast Cancer. 2026 May 29. doi: 10.1038/s41523-025-00887.
    

    >> Share

    
    

    
    Oncol Rep

67. ZUO Y, Xu H, Chen Z, Xiong F, et al
    [Corrigendum] 17?AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA?MB?231 breast cancer cells.
    Oncol Rep. 2026;56:137.
    

    >> Share

    
    

    
    PLoS One

68. LI H, Huang J, Hou J, Chen X, et al
    Machine learning models based on magnetic resonance imaging for predicting Lymphovascular Invasion in Invasive Breast Cancer.
    PLoS One. 2026;21:e0350085.
    

    >> Share

    
    
69. BARATI T, Moghaddam MM, Mokhles F, Mirzaei Z, et al
    Comprehensive multi-omics analysis reveals prognostic, immune, and therapeutic signatures of TNFAIP family genes in breast cancer.
    PLoS One. 2026;21:e0349012.
    

    >> Share

    
    
70. CHUNG EZ, Alberico D, Sannachi L, Dasgupta A, et al
    Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.
    PLoS One. 2026;21:e0346704.
    

    >> Share

    
    
71. PATASOVA K, Che WI, Westerlind H, Diaz-Gallo LM, et al
    Local genetic correlations between systemic sclerosis and common cancer types.
    PLoS One. 2026;21:e0350006.
    

    >> Share

    
    
72. TVETE IF, Klemp M
    Temporal dynamics of prognostic factors in breast cancer survival.
    PLoS One. 2026;21:e0349115.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share